Selected stock price target news of the day - October 15th, 2025

By: Matthew Otto

Genmab Posts Third-Quarter Results for DARZALEX® Amid Continued Global Demand

Genmab A/S reported that Johnson & Johnson recorded worldwide net sales of DARZALEX® (daratumumab) of USD 3,672 million for the third quarter of 2025. Of this total, USD 2,088 million was generated in the United States and USD 1,584 million from international markets.

Under an exclusive licensing agreement, Genmab receives royalties from Johnson & Johnson on sales of both intravenous and subcutaneous versions of DARZALEX, the latter marketed in the U.S. as DARZALEX FASPRO®.

The data reflect the ongoing use of daratumumab in the treatment of multiple myeloma, a blood cancer that affects roughly 35,000 people in the United States annually and more than 160,000 worldwide. Although multiple myeloma remains incurable, treatment developments have improved survival outcomes, with some patients now living beyond six years following diagnosis.

HC Wainwright & Co. Reaffirms Rating and Price Target on Genmab Following Q3 Update

HC Wainwright & Co. analyst Raghuram Selvaraju reiterated a Buy rating and a $40 price target.

Which Analyst has the best track record to show on GMAB?

Analyst Asthika Goonewardene (TRUIST) currently has the highest performing score on GMAB with 6/15 (40%) price target fulfillment ratio. His price targets carry an average of $24.75 (116.47%) potential upside. Genmab A/S stock price reaches these price targets on average within 87 days.

Johnson & Johnson Beats Q3 Estimates, Raises 2025 Outlook, Plans Orthopedics Spinoff

Johnson & Johnson reported third-quarter 2025 results that slightly exceeded expectations, posting adjusted earnings per share of $2.8, beating analyst estimates of $2.76, on revenue of $23.99 billion versus the consensus of $23.76 billion.

Pharmaceutical sales rose 6.8% year-over-year to $15.56 billion, driven by performance from blood cancer drug DARZALEX®, which generated $3.67 billion, nearly matching forecasts of $3.62 billion. Medical device sales also increased 6.8% to $8.43 billion, supported by demand for electrophysiology products.

Following the earnings beat, J&J raised its full-year 2025 guidance, projecting EPS of $10.8 to $10.9 and revenue between $93.5 billion and $93.9 billion, up from prior estimates and above the consensus of $93.46 billion.

J&J also announced plans to separate its $9.2 billion orthopedics division, DePuy Synthes, into an independent, publicly traded firm within 18 to 24 months, its second major spinoff in two years after the $15 billion consumer unit Kenvue in 2023. The orthopedics business, which represents about 10% of J&J’s total revenue and 30% of its MedTech segment, has lagged in growth relative to the rest of the portfolio.

J&J expects overall revenue growth to exceed 5% in 2026, surpassing analysts’ current forecast of 4.6%, and anticipates adjusted earnings to top Wall Street’s $11.39 per share estimate by up to $0.05.

Analyst Ratings Hold Steady as Johnson & Johnson Price Targets Rise an Average of 4.9%

Morgan Stanley analyst Terence Flynn maintained an Equal-Weight rating and raised the price target from $178 to $190.
BofA Securities analyst Tim Anderson kept a Neutral rating and boosted the price target from $198 to $204.

Which Analyst has the best track record to show on JNJ?

Analyst Tim Anderson (BAML) currently has the highest performing score on JNJ with 6/7 (85.71%) price target fulfillment ratio. His price targets carry an average of $9.36 (4.96%) potential upside. Johnson & Johnson stock price reaches these price targets on average within 96 days.

Wells Fargo Lifts Profit Outlook and Investment Banking Revenue Following Asset Cap Removal

Wells Fargo & Co. reported third-quarter 2025 earnings above market expectations, signaling progress following the U.S. Federal Reserve’s decision to lift its regulatory asset cap earlier this year. The bank’s net income rose to $5.59 billion, or $1.66 per share, compared with analysts’ forecasts of $1.55 per share.

Revenue reached $21.43 billion, slightly ahead of the $21.14 billion consensus estimate, as total assets exceeded $2 trillion for the first time. Wells Fargo also increased its return on tangible common equity (ROTCE) goal to 17–18%, up from its prior 15% target.

The provision for credit losses fell to $681 million, compared with $1.07 billion a year earlier, supported by stable consumer loan performance. Investment banking revenue rose 25% to a record $840 million, driven by higher U.S. merger and acquisition volumes, which climbed 33% year over year.

For 2025 guidance, Wells Fargo expects net interest income to stay close to 2024’s $47.7 billion, while noninterest expenses are projected to increase slightly to about $54.6 billion, reflecting higher severance and compensation costs.

Analysts Raise Wells Fargo Price Targets by Up to 8% as Ratings Hold Steady

Morgan Stanley analyst Betsy Graseck maintained an Equal-Weight rating while raising the price target from $95 to $97.
Keefe, Bruyette & Woods analyst David Konrad maintained a Market Perform rating and boosted the price target from $85 to $92.

Which Analyst has the best track record to show on WFC?

Analyst Scott Siefers (PIPER SANDLER) currently has the highest performing score on WFC with 12/12 (100%) price target fulfillment ratio. His price targets carry an average of $9.62 (12.76%) potential upside. Wells Fargo & Co. stock price reaches these price targets on average within 462 days.